Miller Derek sold $1.6M of AMGN

Miller Derek (SVP, Human Resources) sold 3,890 shares of AMGEN INC (AMGN) at $402.54 ($1.57M total) across 2 trades on 2026-08-06.

Original reporting
SEC EDGAR · Miller Derek
Published Aug 7, 2026, 10:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMGN
Neutral
medium confidence
Mentioned
$AMGN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMGNNeutralLow
01

Why it matters

It provides transaction-level details (shares, price, total value, post-sale holdings) but no accompanying company event such as guidance, trial results, or regulatory action.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no fundamental catalyst in the disclosure.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context on total holdings or compensation, signal strength is limited.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-07 after 2026-08-06 insider sale

Background

The article is a SEC Form 4 insider transaction disclosure for Amgen (AMGN).

Company-level read

Ticker impact

$AMGNNeutralMedium confidence
Context

AMGN disclosed an insider open-market sale by SVP Human Resources Miller Derek of 3,890 shares at about $402.54 on 2026-08-06.

Expected impact

Likely minimal near-term impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

Form 4 insider sales are common and the filing provides transaction details without earnings, guidance, or operational changes. The absence of a 10b5-1 plan can raise attention, but the article contains no additional catalyst or company-specific news.

Market effects

No clear sector read-through from a single AMGN insider sale.

None indicated.

None indicated.

Counterpoint

The lack of a 10b5-1 plan could be interpreted by some traders as higher near-term risk, even if the sale size is not clearly material to AMGN’s fundamentals.

Key entities

  • AMGN

    Amgen Inc., the company whose insider transaction was reported.

  • Miller Derek

    SVP, Human Resources at Amgen, reported an open-market sale of shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMGNMed

Freedom Broker downgrades Amgen stock rating on valuation despite raising price target

Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.

$AMGNLow

FDA Approval for AMJEVITA issued to AMGEN INC

The FDA approved a label update for Amgen's AMJEVITA (adalimumab-atto) on 11/05/2026, according to the company. The approval covers the 20 mg/0.4 mL and 40 mg/0.8 mL injectable products, but no new indication was disclosed. This is a routine regulatory update for an already approved product.

$AMGNMed

Amgen’s Repatha reduces heart attack risk in real-world study

Amgen's Repatha (evolocumab) reduced heart attack risk by 20% compared to ezetimibe in a real-world study of 544,103 adults with atherosclerotic cardiovascular disease, according to the company. The four-year study tracked patients from 2017 to 2024, with Repatha showing a lower cumulative incidence of heart attacks (5.88% vs. 7.76%). Amgen's chief medical officer highlighted the study's relevance for treatment decisions.